All News

Allogeneic

Adaptimmune and TCR2 Collaborate to Develop Cell Therapies for Solid Tumors
8 March 2023
Adaptimmune and TCR2 Collaborate to Develop Cell Therapies for Solid Tumors
Adaptimmune Theraputics and TCR2 Theraputics
Mesoblast Phase III Cell Therapy Shows Promise Against Heart Failure  
28 February 2023
Mesoblast Phase III Cell Therapy Shows Promise Against Heart Failure  
Mesoblast has announced that the
Allogeneic Therapies: Can This be the Silver Bullet for All Future Cell Therapy Developers?
25 January 2023
Allogeneic Therapies: Can This be the Silver Bullet for All Future Cell Therapy Developers?
In this guest column, Renu
Can a Smaller Plasmid Produce Huge Benefits? The Power of Small
20 September 2022
Can a Smaller Plasmid Produce Huge Benefits? The Power of Small
Optimizing gene payload begins with
POPULAR NEWS ITEMS
Image
23 March 2023

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image
14 March 2023

Pfizer Invests $43 Billion to Acquire Seagen

Image
2 March 2023

Early Adoption and Partnerships – The Secret to Commercialization Success?

Mind the Gap: Transforming Cell & Gene Therapies from Scientific Success to Available Cures
29 August 2022
Mind the Gap: Transforming Cell & Gene Therapies from Scientific Success to Available Cures
Ohad Karnieli, Founder and CEO
New Technologies for Cell Therapy Manufacturing with Invetech
26 August 2022
New Technologies for Cell Therapy Manufacturing with Invetech
David Hodl, Head of Business
Scaling Clinical Cell and Gene Therapies
28 July 2022
Scaling Clinical Cell and Gene Therapies
In this webinar, discover how
FDA Grants Third RMAT Designation to AlloVir’s T Cell Therapy – Targeting Viruses in Allogeneic Hematopoietic Cell Transplant Patients
21 April 2022
FDA Grants Third RMAT Designation to AlloVir’s T Cell Therapy – Targeting Viruses in Allogeneic Hematopoietic Cell Transplant Patients
AlloVir, has announced the FDA
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image

Pfizer Invests $43 Billion to Acquire Seagen

Image

Early Adoption and Partnerships – The Secret to Commercialization Success?